Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of ZD6474 in combination with Arimidexâversus Arimidexâalone as second-line treatment in patients with hormone-sensitive (recipients) advanced breast cancer (ABC).positive estrogen and/or positive progesterone receptors).[Ensayo en fase II, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de ZD6474 en combinación con Arimidexâfrente a Arimidexâsolo como tratamiento de segunda línea en pacientes con cáncer de mama avanzado (CMA) hormonosensible (receptores de estrógeno positivos y/o receptores de progesterona positivos).]

Next Previous
Trial Profile

A phase II, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of ZD6474 in combination with Arimidexâversus Arimidexâalone as second-line treatment in patients with hormone-sensitive (recipients) advanced breast cancer (ABC).positive estrogen and/or positive progesterone receptors).[Ensayo en fase II, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de ZD6474 en combinación con Arimidexâfrente a Arimidexâsolo como tratamiento de segunda línea en pacientes con cáncer de mama avanzado (CMA) hormonosensible (receptores de estrógeno positivos y/o receptores de progesterona positivos).]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anastrozole (Primary) ; Vandetanib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca AB

Most Recent Events

  • 13 Apr 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top